Revolution Medicines (RVMD) Accounts Payables (2019 - 2026)

Revolution Medicines' Accounts Payables history runs 8 years deep, the most recent figure standing at $80.5 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 69.53% year-over-year to $80.5 million in Q1 2026; TTM through Mar 2026 was $80.5 million, a 69.53% increase from a year earlier, with the FY2025 full-year figure at $64.6 million, up 18.72% from the prior year.
• Accounts Payables climbed to $80.5 million in Q1 2026 per RVMD's latest filing, from $64.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $80.5 million in Q1 2026 and bottomed at $14.1 million in Q2 2022.
• The 5-year median for Accounts Payables is $29.8 million (2023), against an average of $40.0 million.
• Across the five-year window, Accounts Payables decreased 17.45% in 2024 and jumped 206.06% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $21.3 million in 2022, then surged by 190.0% to $61.8 million in 2023, then dropped by 11.91% to $54.4 million in 2024, then grew by 18.72% to $64.6 million in 2025, then grew by 24.64% to $80.5 million in 2026.
• Per Business Quant, the three latest RVMD Accounts Payables figures stand at $80.5 million (Q1 2026), $64.6 million (Q4 2025), and $74.8 million (Q3 2025).